Literature DB >> 8885127

A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation.

A Alak1, S Moy, I Bekersky.   

Abstract

A sensitive and selective high-performance liquid chromatographic (HPLC) method has been developed for the determination of amphotericin B in human serum. After methanol deproteinization, amphotericin B and 3-nitrophenol (internal standard) are separated by reversed-phase chromatography and detected by ultraviolet absorbance. The analysis of human serum after the standard addition of amphotericin B (0.05-200.0 micrograms/mL) demonstrated excellent precision and accuracy over a five-day period. The HPLC assay uses two standard curve ranges. The high sensitivity curve range for low AmBisome dosage (1.0 mg/kg) is 0.05-20.0 micrograms/mL (curve 1), and the second curve range for the higher AmBisome dose regimens (2.5-5.0 mg/kg) is 0.5-200 micrograms/mL (curve 2). The intraday and interday coefficients of variations for standard curve 1 were 0.5-4.6% and 3.0-11.5%, respectively. The limit of quantitation was 0.05 microgram/mL. The intraday and interday coefficients of variation for standard curve 2 were 2.0-3.6 and 6.9-10.1, respectively. No interfering peak at the retention time for Amphotericin B and the internal standard were present in blank serums or serum samples spiked with fifteen potential co-administrated drugs with Amphotericin B treatment. The method was used to quantitate serum concentrations of amphotericin B in patients after the administration of AmBisome, a liposomal formulation of amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885127     DOI: 10.1097/00007691-199610000-00014

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Authors:  I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.

Authors:  I Bekersky; G W Boswell; R Hiles; R M Fielding; D Buell; T J Walsh
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

3.  Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.

Authors:  Ying Hong; Peter J Shaw; Bruce N Tattam; Christa E Nath; John W Earl; Katherine R Stephen; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2006-12-19       Impact factor: 2.953

4.  Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Authors:  T J Walsh; V Yeldandi; M McEvoy; C Gonzalez; S Chanock; A Freifeld; N I Seibel; P O Whitcomb; P Jarosinski; G Boswell; I Bekersky; A Alak; D Buell; J Barret; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.

Authors:  Gudrun Würthwein; Charlotte Young; Claudia Lanvers-Kaminsky; Georg Hempel; Mirjam N Trame; Rainer Schwerdtfeger; Helmut Ostermann; Werner J Heinz; Oliver A Cornely; Hedwig Kolve; Joachim Boos; Gerda Silling; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  Liposomal formulation increases local delivery of amphotericin from bone cement: a pilot study.

Authors:  Brian Cunningham; Alex C McLaren; Christine Pauken; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

7.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Authors:  Jodi M Lestner; Andreas H Groll; Ghaith Aljayyoussi; Nita L Seibel; Aziza Shad; Corina Gonzalez; Lauren V Wood; Paul F Jarosinski; Thomas J Walsh; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.